CINECA IRIS Institutional Research Information System

SCHIRRIPA, MARTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.854
AS - Asia 1.422
EU - Europa 911
SA - Sud America 300
AF - Africa 89
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.579
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.765
SG - Singapore 496
CN - Cina 355
IT - Italia 244
BR - Brasile 241
HK - Hong Kong 220
VN - Vietnam 169
DE - Germania 115
SE - Svezia 97
GB - Regno Unito 84
FR - Francia 82
BG - Bulgaria 79
CA - Canada 59
RU - Federazione Russa 54
AT - Austria 42
IN - India 38
TR - Turchia 33
AR - Argentina 27
FI - Finlandia 24
CI - Costa d'Avorio 23
NG - Nigeria 20
NL - Olanda 20
BD - Bangladesh 18
SN - Senegal 17
JP - Giappone 15
MX - Messico 13
ID - Indonesia 12
EC - Ecuador 11
PL - Polonia 11
UA - Ucraina 11
PK - Pakistan 10
SA - Arabia Saudita 9
IQ - Iraq 8
ZA - Sudafrica 8
CZ - Repubblica Ceca 7
ES - Italia 7
LT - Lituania 7
VE - Venezuela 7
AL - Albania 5
TW - Taiwan 5
UZ - Uzbekistan 5
BE - Belgio 4
CH - Svizzera 4
CO - Colombia 4
EG - Egitto 4
MA - Marocco 4
PA - Panama 4
PE - Perù 4
CL - Cile 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
IL - Israele 3
PH - Filippine 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
BH - Bahrain 2
BJ - Benin 2
CR - Costa Rica 2
EE - Estonia 2
IE - Irlanda 2
JM - Giamaica 2
KE - Kenya 2
KR - Corea 2
KZ - Kazakistan 2
MY - Malesia 2
NI - Nicaragua 2
NP - Nepal 2
OM - Oman 2
PY - Paraguay 2
RO - Romania 2
AU - Australia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BW - Botswana 1
DK - Danimarca 1
ET - Etiopia 1
GD - Grenada 1
GT - Guatemala 1
HR - Croazia 1
HU - Ungheria 1
IM - Isola di Man 1
IR - Iran 1
IS - Islanda 1
KG - Kirghizistan 1
KH - Cambogia 1
LK - Sri Lanka 1
MM - Myanmar 1
MQ - Martinica 1
NZ - Nuova Zelanda 1
QA - Qatar 1
RE - Reunion 1
RS - Serbia 1
SI - Slovenia 1
TH - Thailandia 1
TM - Turkmenistan 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.579
Salva come PNG Salva come JPEG
Città #
Ashburn 316
Singapore 275
Woodbridge 271
Fairfield 222
Hong Kong 214
Santa Clara 202
Houston 166
San Jose 150
Chandler 115
Seattle 109
Dallas 94
Shanghai 86
Cambridge 85
Ann Arbor 80
Sofia 79
Beijing 72
New York 71
Wilmington 70
Boardman 47
Ho Chi Minh City 43
Council Bluffs 42
Vienna 38
São Paulo 36
Lauterbourg 35
Los Angeles 35
Princeton 35
Hanoi 34
Lawrence 31
Ottawa 29
Des Moines 27
Florence 27
Abidjan 23
Medford 23
Bremen 20
Lagos 20
London 20
Istanbul 19
Milan 19
Colorado Springs 18
Dakar 17
Düsseldorf 17
Dearborn 16
Lancaster 16
Redondo Beach 16
Buffalo 15
Serra 14
Tokyo 14
Munich 13
Nanjing 13
San Diego 13
Montreal 12
Frankfurt am Main 11
Pisa 11
Warsaw 11
Rio de Janeiro 10
Curitiba 9
Marseille 9
Nuremberg 9
Phoenix 9
Dong Ket 8
Orem 8
Redwood City 8
Toronto 8
Baltimore 7
Da Nang 7
Denver 7
Rome 7
Shenyang 7
Turku 7
Atlanta 6
Baghdad 6
Brasília 6
Brooklyn 6
Bắc Ninh 6
Chennai 6
Johannesburg 6
Kunming 6
Mexico City 6
Positano 6
Quito 6
Seacroft 6
Ankara 5
Boston 5
Chicago 5
New Delhi 5
Ogden 5
Thái Nguyên 5
Brussels 4
Carrara 4
Changsha 4
Detroit 4
Fuzhou 4
Guangzhou 4
Haiphong 4
Hangzhou 4
Hebei 4
Helsinki 4
Hải Dương 4
Jinan 4
Lusciano 4
Totale 3.781
Salva come PNG Salva come JPEG
Nome #
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 218
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 203
TAS-102 for the treatment of metastatic colorectal cancer 184
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 178
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO 177
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials 170
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib 169
NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients 168
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 and TRIBE trials 167
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: A clinical and molecular proof of concept study 167
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial 165
Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer 159
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib 158
KRAS status and risk of venous thromboembolic events in patients with metastatic colorectal cancer: a case-control study. 157
Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer 141
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer 141
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer 139
Clinical significance of tlr1 i602s polymorphism for patients with metastatic colorectal cancer treated with folfiri plus bevacizumab 137
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 134
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study 132
null 129
Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib 124
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection 124
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial 121
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 120
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 119
Phase II study of single-agent cetuximab in KRAS g13d mutant metastatic colorectal cancer 116
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 112
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study 110
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 109
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 107
The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer 100
null 98
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 94
DPYD c.1905+1G>A and c.2846 A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer. 93
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 89
null 85
First-line chemotherapy for mCRC-a review and evidence-based algorithm 82
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer 72
null 65
null 48
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 44
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 43
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 39
Reply: Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab' 37
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 34
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 33
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers 33
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 32
Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study 19
Totale 5.695
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.081
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.081
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022303 5 14 3 7 57 54 9 7 16 26 10 95
2022/2023439 40 66 31 56 47 55 4 20 84 4 31 1
2023/2024241 19 16 37 4 42 37 24 6 4 2 21 29
2024/20251.236 5 61 71 44 160 169 81 46 105 175 102 217
2025/20261.903 108 197 173 208 173 161 278 126 133 205 88 53
2026/202711 11 0 0 0 0 0 0 0 0 0 0 0
Totale 5.695